StreetInsider.com News Articles

Form D Tempest Therapeutics,

Wed, 14 Oct 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27183153.html

Form 4 Tempest Therapeutics, For: Sep 22 Filed by: Smith Nancy Freda

Fri, 02 Oct 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20261002/27142525.html

Form 3 Tempest Therapeutics, For: Sep 22 Filed by: Smith Nancy Freda

Fri, 02 Oct 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20261002/27142511.html

Form 424B3 Tempest Therapeutics,

Fri, 02 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261002/27141994.html

Form EFFECT Tempest Therapeutics,

Fri, 02 Oct 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20261002/27138605.html

Form 8-K Tempest Therapeutics, For: Sep 22

Mon, 28 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260928/27114487.html

Tempest Therapeutics (TPST) files for 9.53M share offering by selling stockholders

Fri, 25 Sep 2026 16:45:32 -0400

Tempest Therapeutics (NASDAQ: TPST) files for up to 9,534,164 share offering by selling stockholders.

Tempest Therapeutics (TPST) files for 9.53M share offering by selling stockholders

Fri, 25 Sep 2026 16:45:32 -0400

Tempest Therapeutics (NASDAQ: TPST) files for up to 9,534,164 share offering by selling stockholders.

Form S-3 Tempest Therapeutics,

Fri, 25 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260925/27107765.html

Tempest Therapeutics names Nancy Freda-Smith to its board

Wed, 23 Sep 2026 08:00:24 -0400

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company, has appointed Nancy Freda-Smith to its board of directors, where she will also serve as Chair of the Audit Committee, according to a press release.

Freda-Smith brings more than 30 years of experience in corporate governance, financial reporting, enterprise risk management, and regulatory compliance. She most recently served as Chief Audit and Risk Officer at Ralph Lauren, where she oversaw internal audit, Sarbanes-Oxley Act compliance, enterprise risk management, asset protection, and cybersecurity resilience across operations in more than 30 countries, covering more than $7 billion in revenue.

Previously, she served as an Independent

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

Wed, 23 Sep 2026 08:00:00 -0400

Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companies

BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that Nancy Freda-Smith has been appointed to its board of directors and will serve as Chair of the Audit Committee.

“We are delighted to welcome Nancy to our board,” said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. “As an experienced board

Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors

Wed, 23 Sep 2026 08:00:00 -0400

Accomplished finance and enterprise executive with over 20 years of global leadership in multinational and Fortune 500 companies

“We are delighted to welcome Nancy to our board,” said Matt Angel, Ph.D., President and Chief Executive Officer of Tempest. “As an experienced board

Form 8-K Tempest Therapeutics, For: Sep 14

Thu, 17 Sep 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260917/27076706.html

Form DEFA14A Tempest Therapeutics,

Wed, 16 Sep 2026 16:39:00 -0400

si-local-file:///var/storage/secattach/20260916/27070806.html

Form 8-K Tempest Therapeutics, For: Sep 15

Wed, 16 Sep 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260916/27070786.html

Form 8-K Tempest Therapeutics, For: Sep 11

Tue, 15 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260915/27064890.html

Tempest Therapeutics options CD7 lentiviral CAR-T platform from Senlang

Tue, 15 Sep 2026 16:05:41 -0400

Tempest Therapeutics (Nasdaq: TPST) has entered into an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd. to potentially license Senlang's CD7-targeted lentiviral vector platform and a portfolio of in vivo CAR-T product candidates, according to a press release dated Sept. 15, 2026.

The portfolio includes a BCMA/GPRC5D dual-targeting in vivo CAR-T candidate currently in Phase 1 dose escalation for relapsed/refractory multiple myeloma, along with additional candidates targeting hematologic malignancies and autoimmune diseases.

Senlang's platform uses targeted lentiviral vectors to deliver CAR transgenes to endogenous CD7-positive T cells and natural killer cells, generating CAR-T and CAR-NK cells directly within the patient, bypassing

Tempest Therapeutics options CD7 lentiviral CAR-T platform from Senlang

Tue, 15 Sep 2026 16:05:41 -0400

Tempest Therapeutics options CD7 lentiviral CAR-T platform from Senlang

Tue, 15 Sep 2026 16:05:41 -0400

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

Tue, 15 Sep 2026 16:05:00 -0400

-Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year

-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate is in Phase 1 dose escalation for relapsed/refractory multiple myeloma

-Early clinical observations demonstrate in vivo CAR-T generation and expansion at the current highest evaluable dose, with an initial safety profile supporting continued dose escalation

-Additional pipeline candidates would expand Tempest’s immune reset portfolio across hematologic malignancies and autoimmune diseases

BRISBANE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Tempest

Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

Tue, 15 Sep 2026 16:05:00 -0400

-Transaction complements Tempest’s existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year

-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate is in Phase 1 dose escalation for relapsed/refractory multiple myeloma

-Early clinical observations demonstrate in vivo CAR-T generation and expansion at the current highest evaluable dose, with an initial safety profile supporting continued dose escalation

-Additional pipeline candidates would expand Tempest’s immune reset portfolio across hematologic malignancies and autoimmune diseases

BRISBANE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Tempest

Tempest Therapeutics raises $2.5M in private placement

Fri, 11 Sep 2026 08:00:15 -0400

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company, announced a private placement deal that could raise up to $7.5 million in total proceeds, according to a company statement.

The offering involves 3,105,591 shares of common stock, or pre-funded warrants in lieu thereof, at a combined purchase price of $0.805 per share. The transaction also includes two series of warrants — series C and series D — each covering up to 3,105,591 shares at an exercise price of $0.805 per share.

The initial gross proceeds are expected to be approximately $2.5 million, before placement agent fees and other expenses. If both warrant

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

Fri, 11 Sep 2026 08:00:00 -0400

$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants

BRISBANE, Calif. , Sept. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591 shares of common stock (or pre-funded warrant in lieu thereof), series C warrants to purchase up to 3,105,591 shares of common stock and series D

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

Fri, 11 Sep 2026 08:00:00 -0400

$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants

Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:30:00 -0400

BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that Matt Angel, Ph.D., Tempest’s President and Chief Executive Officer, will present at the H.C. Wainwright 28^th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. ET.

The webcast will be posted to Tempest’s website at https://ir.tempesttx.com and will be archived for two weeks following the presentation.

About Tempest Therapeutics

Tempest